We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+2.71%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.21B
AUM Growth
-$76.7M
Cap. Flow
-$36.6M
Cap. Flow %
-3.01%
Top 10 Hldgs %
64.48%
Holding
49
New
3
Increased
11
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$47.8M
2
NTLA icon
Intellia Therapeutics
NTLA
+$38.4M
3
WGS icon
GeneDx Holdings
WGS
+$34.6M
4
GPCR icon
Structure Therapeutics
GPCR
+$15.9M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$8.56M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$36.4M
2
ILMN icon
Illumina
ILMN
+$23.1M
3
MXCT icon
MaxCyte
MXCT
+$22.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$20.1M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 99.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
26
Fate Therapeutics
FATE
$291M
$11.7M 0.96%
2,050,000
– –
IPSC icon
27
Century Therapeutics
IPSC
$357M
$11.1M 0.92%
3,206,380
– –
TWST icon
28
Twist Bioscience
TWST
$6.29B
$10.6M 0.87%
700,000
-245,000
-26% -$5.41M
ABSI icon
29
Absci
ABSI
$1.35B
$9.44M 0.78%
5,393,260
-1,970,000
-27% -$4.77M
PRME icon
30
Prime Medicine
PRME
$508M
$9.03M 0.74%
734,350
– –
DICE
31
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$8.88M 0.73%
310,000
+145,000
+88% +$4.29M
OPRX icon
32
OptimizeRx
OPRX
$123M
$7.32M 0.6%
500,000
+240,000
+92% +$4.02M
INCY icon
33
Incyte
INCY
$24B
$5.6M 0.46%
77,500
– –
GLUE icon
34
Monte Rosa Therapeutics
GLUE
$1.3B
$3.98M 0.33%
510,882
– –
TNGX icon
35
Tango Therapeutics
TNGX
$4.43B
$3.95M 0.33%
+1,000,000
New +$5.8M
SRPT icon
36
CALL
Sarepta Therapeutics
SRPT
$1.68B
$3.45M 0.28%
+25,000
New +$3.24M
OMIC
37
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.63M 0.13%
44,857
– –
NVTA
38
DELISTED
Invitae Corporation
NVTA
$1.4M 0.12%
1,038,388
-8,000,000
-89% -$15.8M
EXAI
39
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$1.13M 0.09%
213,900
– –
LIAN
40
DELISTED
LianBio American Depositary Shares
LIAN
$403K 0.03%
206,415
– –
KRON
41
DELISTED
Kronos Bio
KRON
$181K 0.01%
123,839
– –
ARVN icon
42
Arvinas
ARVN
$520M
– –
-200,000
Closed -$6.84M
DH icon
43
Definitive Healthcare
DH
$73.9M
– –
-360,000
Closed -$3.96M
KROS icon
44
Keros Therapeutics
KROS
$200M
– –
-65,000
Closed -$3.12M
MRNA icon
45
CALL
Moderna
MRNA
$21.9B
– –
-30,000
Closed -$5.39M
MRNA icon
46
Moderna
MRNA
$21.9B
– –
-60,000
Closed -$10.8M
VEEV icon
47
Veeva Systems
VEEV
$33.5B
– –
-50,000
Closed -$8.07M
WVE icon
48
Wave Life Sciences
WVE
$1.13B
– –
-200,000
Closed -$1.4M
MRTX
49
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-100,000
Closed -$4.53M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Casdin Capital held 49 positions worth $1.21B, down 5.9% from $1.29B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Casdin Capital withdrew a net $36.6M in Q1 2023, closing 8 positions and reducing 10 holdings. Its most notable exit was Moderna, an estimated $10.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Structure Therapeutics worth $16.1M.

  • Casdin Capital's largest Q1 2023 buy was Structure Therapeutics: 677,017 shares worth $16.1M.
  • Casdin Capital added most to Relay Therapeutics in Q1 2023, an estimated $47.8M increase.
  • Casdin Capital's biggest Q1 2023 reduction was Blueprint Medicines, cutting an estimated $36.4M.
  • Casdin Capital fully exited Moderna in Q1 2023, selling an estimated $10.8M.
  • Casdin Capital's ten largest holdings make up 64% of its $1.21B portfolio in Q1 2023.
  • Casdin Capital opened 3 new positions and closed 8 in Q1 2023.
  • Casdin Capital's portfolio value fell 5.9% quarter-over-quarter to $1.21B.

Based on Casdin Capital's 13F filing for Q1 2023, filed 15 May 2023.